Bicara Therapeutics Inc (NASDAQ: BCAX)’s stock price has increased by 0.67 compared to its previous closing price of 8.94. However, the company has seen a -4.56% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-11 that MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX’s durability argument and deep response rates could drive long-term value if validated in future studies.
Is It Worth Investing in Bicara Therapeutics Inc (NASDAQ: BCAX) Right Now?
There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCAX is 32.77M and currently, short sellers hold a 15.52% ratio of that float. The average trading volume of BCAX on June 26, 2025 was 826.43K shares.
BCAX’s Market Performance
BCAX stock saw a decrease of -4.56% in the past week, with a monthly decline of -9.82% and a quarterly a decrease of -31.30%. The volatility ratio for the week is 7.27%, and the volatility levels for the last 30 days are 9.25% for Bicara Therapeutics Inc (BCAX). The simple moving average for the last 20 days is -12.91% for BCAX stock, with a simple moving average of -44.10% for the last 200 days.
Analysts’ Opinion of BCAX
Many brokerage firms have already submitted their reports for BCAX stocks, with Wells Fargo repeating the rating for BCAX by listing it as a “Equal Weight.” The predicted price for BCAX in the upcoming period, according to Wells Fargo is $8 based on the research report published on May 23, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see BCAX reach a price target of $8. The rating they have provided for BCAX stocks is “Underweight” according to the report published on April 17th, 2025.
Wedbush gave a rating of “Outperform” to BCAX, setting the target price at $31 in the report published on February 06th of the current year.
BCAX Trading at -26.38% from the 50-Day Moving Average
After a stumble in the market that brought BCAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.96% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAX starting from Meisner Lara, who sale 15,829 shares at the price of $10.43 back on Jun 16 ’25. After this action, Meisner Lara now owns 0 shares of Bicara Therapeutics Inc, valued at $165,096 using the latest closing price.
Stock Fundamentals for BCAX
The total capital return value is set at -0.23.
Based on Bicara Therapeutics Inc (BCAX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -150.78.
Currently, EBITDA for the company is -67.75 million with net debt to EBITDA at 4.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.62.
Conclusion
In conclusion, Bicara Therapeutics Inc (BCAX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
